Stimulation of primary human endothelial cell proliferation by IFN1

Journal of Immunology

Volumn 170, Issue 11, 2003, Pages 5373-5381

  Gomez, Dolores ^a   Reich, Nancy C ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL EXTRACT; INTERFERON; NEUTRALIZING ANTIBODY; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; THYMIDINE;

ARTICLE; CELL COUNT; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PHASE; CELL FUNCTION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA MICROARRAY; DNA SYNTHESIS; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNITY; PRIORITY JOURNAL; PROTEIN FAMILY; SIGNAL TRANSDUCTION;

EID: 0037852129     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.11.5373     Document Type: Article

References (57)

1. Krown, S. E. 2001. Management of Kaposi sarcoma: the role of interferon and thalidomide. Curr. Opin. Oncol. 13:374.
2. Ezekowitz, R. A., J. B. Mulliken, and J. Folkman. 1992. Interferon α-2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med. 326:1456.
3. Gibbons, G. H., and V. J. Dzau. 1994. The emerging concept of vascular remodeling. N. Engl. J. Med. 330:1431.
4. Mantovani, A., F. Bussolino, and M. Introna. 1997. Cytokine regulation of endothelial cell function: from molecular level to the bedside. Immunol. Today 18:231.
5. Krishnaswamy, G., J. Kelley, L. Yerra, J. K. Smith, and D. S. Chi. 1999. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J. Interferon Cytokine Res. 19:91.
6. Hanahan, D., and J. Folkman. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell 86:353.
7. Folkman, J. 1995. Seminars in medicine of the Beth Israel Hospital, Boston: clinical applications of research on angiogenesis. N. Engl. J. Med. 333:1757.
8. Marchuk, D. A. 2001. Pathogenesis of hemangioma. J. Clin. Invest. 107:665.
9. Boshoff. C., and R. Weiss. 2002. AIDS-related malignancies. Nat. Rev. Cancer 2:373.
10. Darnell, J. E., Jr., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415.
11. Stark, G. R., I. M. Kerr, B. R. Williams, R. H. Silverman, and R. D. Schreiber. 1998. How cells respond to interferons. Anna. Rev. Biochem. 67:227.
12. O'Shea, J. J., M. Gadina, and R. D. Schreiber. 2002. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109:S121.
13. Ihle, J. N., B. A. Witthuhn, F. W. Quelle, K. Yamamoto, and O. Silvennoinen. 1995. Signaling through the hematopoietic cytokine receptors. Annu. Rev. Immunol. 13:369.
14. Gilmour, K. C., and N. C. Reich. 1995. Signal transduction and activation of gene transcription by interferons. Gene Expression 5:1.
15. Leonard, W. J., and J. J. O'Shea. 1998. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16:293.
16. Martinez-Moczygemba, M., M. J. Gutch, D. L. French, and N. C. Reich. 1997. Distinct STAT structure promotes interaction of STAT2 with the p48 subunit of the interferon-a-stimulated transcription factor ISGF3. J. Biol. Chem. 272:20070.
17. McBride, K. M., G. Banninger, C. McDonald, and N. C. Reich. 2002. Regulated nuclear import of the STAT1 transcription factor by direct binding of importin-α. EMBO J. 21:1754.
18. Chin, Y. E., M. Kitagawa, W. C. Su, Z. H. You, Y. Iwamoto, and X. Y. Fu. 1996. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/ CIP1 mediated by STATI. Science 272:719.
19. Bromberg, J. F., C. M. Horvath, Z. Wen, R. D. Schreiber. and J. E. Darnell, Jr. 1996. Transcriptionally active Statl is required for the antiproliferative effects of both interferon α and interferon γ. Proc. Natl. Acad. Sci. USA 93:7673.
20. Meinke, A., F. Barahmand-Pour, S. Wohrl, D. Stoiber. and T. Decker. 1996. Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons, Mol. Cell. Biol. 16:6937.
21. Fish, E. N., S. Uddin, M. Korkmaz, B. Majchrzak, B. J. Druker, and L. C. Platanias. 1999. Activation of a CrkL-stat5 signaling complex by type I interferons. J. Biol. Chem. 274:571.
22. Yang, C. H., A. Murti, and L. M. Pfeffer. 1998. STAT3 complements defects in an interferon-resistant cell line: evidence for an essential role for STAT3 in interferon signaling and biological activities. Proc. Nad. Acad. Sci. USA 95:5568.
23. Turkson, J., T. Bowman, R. Garcia, E. Caldenhoven, R. P. De Groot, and R. Jove. 1998. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. 18:2545.
24. Bromberg, J. F., C. M. Horvath, D. Besser, W. W. Lathem, and J. E. Darnell, Jr. 1998. Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. 18:2553.
25. Bunting, K. D., H. L. Bradley, T. S. Hawley, R. Moriggl, B, P. Sorrentino, and J. N. Ihle. 2002. Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood 99:479.
26. Nieborowska-Skorska, M., M. A. Wasik, A. Slupianek, P. Salomoni, T. Kitamura, B. Calabretta. and T. Skorski. 1999. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med. 189:1229.
27. Lacronique, V., A. Boureux, V. D. Valle, H. Poirel, C. T. Quang, M. Mauchauffe, C. Berthou, M. Lessard, R. Berger, J. Ghysdael, and O. A. Bernard, 1997. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278:1309.
28. Schwaller, J., E. Parganas, D. Wang, D. Cain, J. C. Aster, I. R. Williams, C. K. Lee, R. Gerthner, T. Kitamura, J. Frantsve. et al. 2000. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol. Cell 6:693.
29. Bromberg, J. F., M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell, C. Albanese, and J. E. Darnell, Jr. 1999. Stat3 as an oncogene. Cell 98:295.
30. Onishi. M., T. Nosaka, K. Misawa, A. L. Mui, D. Gorman. M. McMahon, A. Miyajima, and T. Kitamura. 1998. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol. Cell. Biol. 18:3871.
31. Sellati, T. J., M. J. Bums, M. A. Ficazzola, and M. B. Furie. 1995. Borrelia burgdorferi up-regulates expression of adhesion molecules on endothelial cells and promotes transendothelial migration of neutrophils in vitro. Infect. Immun. 63:4439.
32. Muller, A. M., M. I. Hermanns, C. Skrzynski, M. Nesslinger, K. M. Muller, and C. J. Kirkpatrick. 2002. Expression of the endothelial markers PECAM-1, vWf, and CD34 in vivo and in vitro. Exp. Mol. Pathol. 72:221.
33. Foster, G. R., and N. B. Finter. 1998. Are all type I human interferons equivalent? J. Viral Hepat. 5:143.
34. Hubbell, H. R., R. S. Liu, and B. L. Maxwell. 1984. Independent sensitivity of human tumor cell lines to interferon and double-stranded RNA. Cancer Res. 44:3252.
35. McKendry, R., J. John, D. Flavell, M. Muller, I. M. Kerr, and G. R. Stark. 1991. High-frequency mutagenesis of human cells and characterization of a mutant unresponsive to both α and γ interferons. Proc. Natl. Acad Sci. USA 88:11455.
36. Owaki, M., and Y. Kawade. 1972. Inhibition of multiplication of mouse cells in culture by interferon preparations. Acta Virol. 16:477.
37. Uddin, S., B. Majchrzak, J. Woodson, P. Arunkumar, Y. Alsayed, R. Pine, P. R. Young, E. N. Fish, and L. C. Platanias. 1999. Activation of the p38 mitogen-activated protein kinase by type I interferons. J. Biol. Chem. 274:30127.
38. Goh, K. C., S. J. Haque, and B. R. Williams. 1999. p38 MAP kinase is required for STATI serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 18:5601.
39. Arora, T., G. Floyd-Smith, M. J. Espy, and D. F. Jelinek. 1999. Dissociation between IFN-a-induced anti-viral and growth signaling pathways. J. Immunol. 162:3289.
40. Uddin, S., E. N. Fish, D. A. Sher, C. Gardziola, M. F. White, and L. C. Platanias. 1997. Activation of the phosphatidylinositol 3-kinase serine kinase by IFN-α. J. Immunol. 158:2390.
41. Yang, C. H., A. Murti, S. R. Pfeffer, L. Basu, J. G. Kim, and L. M. Pfeffer. 2000. IFNα/β promotes cell survival by activating NF-κB. Proc. Natl. Acad. Sci. USA 97:13631.
42. Yang, C. H., A. Murti, S. R. Pfeffer, J. G. Kim, D. B. Donner, and L. M. Pfeffer. 2001. Interferon α/β promotes cell survival by activating nuclear factor KB through phosphatidylinositol 3-kinase and Akt. J. Biol. Chem. 276:13756.
43. Der. S. D., A. Zhou. B. R. Williams. and R. H. Silverman. 1998. Identification of genes differentially regulated by interferon α, β or γ using oligonucleotide atrays. Proc. Natl. Acad. Sci. USA 95:15623.
44. De Veer, M. J., M. Holko, M. Frevel, E. Walker, S. Der, J. M. Paranjape, R. H. Silverman, and B. R. Williams. 2001. Functional classification of interferon-stimulated genes identified using microarrays. J. Leukocyte Biol. 69:912.
45. Bicknell, R. 1996. Endothelial cell culture. In Handbooks in Practical Animal Cell Biology. Cambridge University Press, New York.
46. Tellides. G., D. A. Tereb, N. C. Kirkiles-Smith, R. W. Kim, J. H. Wilson, J. S. Schechner, M. I. Lorber, and J. S. Pober. 2000. Interferon-γ elicits arteriosclerosis in the absence of leukocytes. Nature 403:207.
47. Sica. G., L. Fabbroni, L. Castagnetta, M. Cacciatore, and M. Pavone-Macaluso. 1989. Antiproliferative effect of interferons on human prostate carcinoma cell lines. Urol. Res. 17:111.
48. Warner. S. J., G. B. Friedman. and P. Libby. 1989. Immune interferon inhibits proliferation and induces 2'-5'-oligoadenylate synthetase gene expression in human vascular smooth muscle cells. J. Clin. Invest. 83:1174.
49. Lee, B. S., E. A. Stewart, M. Sahakian, and R. A. Nowak. 1998. Interferon-α is a potent inhibitor of basic fibroblast growth factor-stimulated cell proliferation in human uterine cells. Am. J. Reprod. Immunol. 40:19.
50. Da Silva, A. J., M. Brickelmaier, G. R. Majeau, A. V. Lukashin, J. Peyman, A. Whitty, and P. S. Hochman. 2002. Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-α2b vs. IFN-β1a: understanding the functional relationship between distinct type I interferons that act through a common receptor. J. Interferon Cytokine Res. 22:173.
51. Krebs, D. L., and D. J. Hilton. 2000. SOCS: physiological suppressors of cytokine signaling. J. Cell Sci. 113:2813.
52. Raefsky, E. L., L. C. Platanias, N. C. Zoumbos, and N. S. Young. 1985. Studies of interferon as a regulator of hematopoietic cell proliferation. J. Immunol. 135:2507.
53. Verma, D. S., G. Spitzer. and J. U. Gutterman. 1981. Measurement of effects of human leukocyte interferon on human granulocyte colony-forming cells in vitro. Methods Enzymol. 79:520.
54. Liu, X., Y. Sun, R. A. Weinberg, and H. F. Lodish. 2001. Ski/Sno and TGF-β signaling. Cytokine Growth Factor Rev. 12:1.
55. Gorbacheva, V. Y., D. Lindner, G. C. Sen, and D. J. Vestal. 2002. The interferon (IFN)-induced GTPase, mGBP-2: role in IFN-γ-induced murine fibroblast proliferation. J. Biol. Chem. 277:6080.
56. Ikeda, H., L. J. Old, and R. D. Schreiber. 2002. The roles of IFN γ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13:95.
57. Singh, R. K., M. Gutman, C. D. Bucana, R. Sanchez, N. Llansa, and I. J. Fidler. 1995. Interferons a and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA 92:4562.